Klinefelter syndrome is a rare condition in which one or more extra X chromosomes are present in a male. About 60% of the embryos with Klinefelter’s syndrome do not survive the fetal period. Mosaic Klinefelter syndrome occurs when some of the cells in the body have an extra X chromosome. These males can have the same or milder symptoms. Klinefelter syndrome is not considered an inherited condition.
The risk of Klinefelter syndrome reoccurring in another pregnancy is not increased about the general population risk.
According to the researchers of national human research institutes, the Klinefelter syndrome condition cannot be diagnosed easily, due to its unidentifiable symptoms and signs among males. The signs of this condition are different and also gets overlap with symptoms of other health disorders. Due to this, various healthcare organizations such as the NIH and FDA are increasing their awareness regarding this health disorder, by stressing the parents to conduct all kinds of health check-ups to identify this disease.
This syndrome can be prevented if detected at early stage and also can be prevented from development. Moreover, the awareness among the population reading this syndrome is also increasing. In February 2016, Lupin Pharmaceuticals, Inc. launched a testosterone topical solution in the U.S. for males, who are suffering from hormone deficiencies.
Some of the key players in the Global klinefelter syndrome treatment market are is Allergan plc, AbbVie, Inc., Endo Pharmaceuticals, Inc., Kyowa Kirin International plc, Eli Lilly and Company, Mylan N.V., Lupin Pharmaceuticals, Pfizer, Inc.
コメント